Although the combined targeting of VEGF and Ang‐2 has been described previously (Brown et al, 2010; Hashizume et al, 2010; Koh et al, 2010b; Daly et al, 2013; Gerald et al, 2013; Kienast et al, 2013; Rigamonti et al, 2014), this is the first study that explores the potential of dual anti‐angiogenic therapy in orthotopic brain tumors. The gene discussed is VEGFA; the disease is brain neoplasm.